Skip to main content
. 2020 Oct;8(19):1225. doi: 10.21037/atm-20-4544

Table S2. Detection of MET mutation in three types of samples from PTC patients.

Sample cfDNA FFPE gDNA
Coverage VarReads VarFreq Coverage VarReads VarFreq Coverage VarReads VarFreq
1 30,836 1,348 4.37% 5,312 0 0 3,279 0 0
2 37,213 576 1.55% 6,346 0 0 2,207 0 0
3 64,754 3,096 4.78% 3,442 0 0 2,236 0 0
4 41,093 1,331 3.24% 5,283 0 0 3,732 0 0
5 23,608 10,622 44.99% 3,747 1,823 48.65% 2,416 1,234 51.08%
8 56,117 4,231 7.54% 2,658 102 3.84% 1,922 0 0
9 22,847 0 0 6,917 361 5.22% 1,336 0 0
10 31,654 5,322 16.81% 4,688 2,165 46.18% 2,939 1,483 50.46%

MET mutations were not detected in three types of samples from patients 5 and 7. PTC, papillary thyroid carcinoma; cfDNA, cell-free DNA; FFPE, formalin-fixed and paraffin-embedded.